Other research analysts also recently issued research reports about the company. Zacks Investment Research upgraded DaVita HealthCare Partners from a hold rating to a buy rating and set a $87.00 target price on the stock in a research note on Tuesday, July 5th. JPMorgan Chase & Co. boosted their target price on DaVita HealthCare Partners from $74.00 to $75.00 and gave the company a neutral rating in a research note on Tuesday, August 9th. Citigroup Inc. began coverage on DaVita HealthCare Partners in a research note on Tuesday, September 6th. They issued a neutral rating and a $71.00 target price on the stock. Bank of America Corp. downgraded DaVita HealthCare Partners from a buy rating to a neutral rating and set a $70.00 target price on the stock. in a research note on Tuesday, September 6th. Finally, TheStreet downgraded DaVita HealthCare Partners from a buy rating to a hold rating in a research note on Monday, August 8th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company. The company has a consensus rating of Hold and a consensus target price of $75.50.
Shares of DaVita HealthCare Partners (NYSE:DVA) traded up 0.05% during midday trading on Thursday, reaching $63.02. The company’s stock had a trading volume of 471,487 shares. DaVita HealthCare Partners has a 12 month low of $61.36 and a 12 month high of $78.94. The stock has a market capitalization of $13.04 billion, a P/E ratio of 36.66 and a beta of 0.96. The stock’s 50-day moving average is $64.49 and its 200 day moving average is $72.37.
DaVita HealthCare Partners (NYSE:DVA) last issued its quarterly earnings results on Monday, August 8th. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $0.03. DaVita HealthCare Partners had a return on equity of 16.48% and a net margin of 2.51%. The business had revenue of $3.72 billion for the quarter, compared to the consensus estimate of $3.67 billion. During the same quarter in the previous year, the company posted $0.95 earnings per share. DaVita HealthCare Partners’s revenue for the quarter was up 8.2% compared to the same quarter last year. On average, analysts expect that DaVita HealthCare Partners will post $3.76 earnings per share for the current fiscal year.
In related news, COO Michael David Staffieri sold 20,262 shares of the business’s stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $73.09, for a total transaction of $1,480,949.58. Following the transaction, the chief operating officer now directly owns 52,279 shares in the company, valued at $3,821,072.11. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 2.10% of the company’s stock.
A number of institutional investors have recently modified their holdings of the stock. Glenmede Trust Co. NA raised its stake in DaVita HealthCare Partners by 63.9% in the first quarter. Glenmede Trust Co. NA now owns 3,906 shares of the company’s stock valued at $286,000 after buying an additional 1,523 shares in the last quarter. Teachers Advisors Inc. raised its stake in DaVita HealthCare Partners by 45.9% in the first quarter. Teachers Advisors Inc. now owns 273,527 shares of the company’s stock valued at $20,071,000 after buying an additional 86,022 shares in the last quarter. ING Groep NV bought a new stake in DaVita HealthCare Partners during the first quarter valued at $278,000. Aviva PLC raised its stake in DaVita HealthCare Partners by 1.1% in the first quarter. Aviva PLC now owns 108,300 shares of the company’s stock valued at $7,947,000 after buying an additional 1,181 shares in the last quarter. Finally, Credit Agricole S A raised its stake in DaVita HealthCare Partners by 8.7% in the first quarter. Credit Agricole S A now owns 81,202 shares of the company’s stock valued at $5,958,000 after buying an additional 6,498 shares in the last quarter. Hedge funds and other institutional investors own 83.55% of the company’s stock.
About DaVita HealthCare Partners
DaVita HealthCare Partners Inc is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. Its segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives. Its Kidney Care division is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD).
Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.